May Cho

GI oncologist and researcher @UCIAntiCancer. Tweets are my own opinions. RTs are not commercial endorsements.

[May Cho @MayCho_MD]

Three journeys of young onset colorectal cancers! “Dr. Cho told me to let her worry about the cancer and for me to worry about starting my brewery,” he recalled. Trinity County Brewing Company @TrinityBrewery opened in May 2020! https://t.co/naizYplK63 @sepideh_gholami @HalabiMd

[May Cho @MayCho_MD]

@jgong15 @DrHendifar @CSCancerCenter @CedarsSinai @NEJM @DrHendifar killing it everytime with NEJM papers!!!

[May Cho @MayCho_MD]

@NCAATennis @uclawtennis So proud of Kate! Got the intensity from dad!

[Arndt Vogel @ArndtVogel]

ctDNA-based MRD & survival in resectable CRC
@NatureMedicine
https://t.co/Td1vdPs0ql
🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts
👉shorter DFS in MRD+ patients
👉Better outcome after sustained ctDNA clearance in response to ACT
🧐What else do we need to implement into clinical practice?
@myESMO

[Dr. Marwan G. Fakih @mgfakih]

Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite … https://t.co/v7eeQQkRWj
Our single center experience as summarized by our super Fellow Dr. Annie Xioa supports early discontinuation in settings of Clinical CR.

[Michael Cecchini @Cecchini_OncMD]

I will be riding in my 6th closer to free bike ride on 9/7/2024. The ride is a great experience to join the Yale Cancer Center community and support cancer research. Please support my ride at the following link:

https://t.co/YAD02gt21y

My goal is to raise at least $500!

[Dr. Cathy Eng @CathyEngMD]

From @asco as led by: @ajscott40 @sepidah_gholami @MyriamChalabi @HKennecke @MayCho_MD @manjuggm @JoshSmithMDPhD : Management of Locally Advanced Rectal Cancer: ASCO Guideline https://t.co/YTwpSSz0mk #crcsm #rectalcancer #cancer #CancerResearch @OncoAlert

[May Cho @MayCho_MD]

Who would not love working with @HKennecke!!!

[Sepideh Gholami, MD, MAS, FACS, FSSO @sepideh_gholami]

@HKennecke @ASCO @ajscott40 @VanMorrisMD @manjuggm @jonathanloree @JoshSmithMDPhD @jordanberlin5 @MayCho_MD @lisakachnic1 Loved working with you on this! Your insights are always so valuable.

[May Cho @MayCho_MD]

@DocCatenacci Finally we no longer need to have this broken record debate in every single GI ASCO anymore!!!

[May Cho @MayCho_MD]

Universe listens to your inner voice. Been wanting to meet this inspiring @realbowtiedoc and got a chance to have “peer mentoring” session and learned how he’s improving much needed pall care for GI Onc pts since the first day of their journeys!

[Dr Joseph McCollom DO @realbowtiedoc]

A favorite #SuppOncSelfies📸 with luminary @MayCho_MD at @ASCOTECAG lounge. These 1-on-1 mentoring sessions are so cherished. Her wisdom "That queasy feeling you get is moving from a comfort to a growth mindset" So honored to have time at the table with her #ASCO24 #GIonc

[May Cho @MayCho_MD]

@CathyEngMD @AnwaarSaeed3 We should have girls/mentees’ trip to Nashville! @CathyEngMD you mentor many…it will be a big group. @AnwaarSaeed3 @NVijayvergiaMD @rutikamehtaMD Sep and many more…

[Erman Akkus @Erman_Akkus]

💊Adding durvalumab plus bevacizumab to TACE in unresectable HCC
EMERALD-1, @ASCO GI24
@JCO_ASCO

✅D+B+TACE vs TACE
mPFS: 15.0 vs 8.2 mo, HR: 0.77 (0.61–0.98) p=0.032
❌D+TACE vs TACE
mPFS: 10.0 vs 8.2 mo, HR: 0.94 (0.75–1.19) p=0.638

👉https://t.co/3u26NAUI7v

⁉️Whether it may change the practice may depend on OS. Patients continue to be followed for OS

@JCOPO_ASCO @liver_cancer @BCLC_group @TimGreten @kmody29 @Amitmahipal79 @AndrewMMoon
#cancer #oncology #liver #hcc #MedX

[May Cho @MayCho_MD]

Only @jgong15 can do this! Has been writing/publishing dual/triple since fellowship @COHMedOnc with @mgfakih and @montypal!

[OncoDaily @oncodaily]

Dual publication on @JCOPO_ASCO - @jgong15
@theNCI @JCO_ASCO @ASCOPost

#Cancer #CancerResearch #OncoDaily #Oncology #TreatmentRefractoryTumors #PrecisionOncology

https://t.co/nJMRbdtf1t

[May Cho @MayCho_MD]

@jgong15 so proud of you!!!👏

[Jun Gong @jgong15]

So cool, colleague pointed this out to me today. Unexpected! But deeply honored to be on the cover @OncLive with esteemed #GI onc colleagues @DrElkhoueiry @rachnatshroff @AnwaarSaeed3 @covey_md Dr. Michael Morse

https://t.co/Ci3UISYlGD

@CSCancerCenter

[May Cho @MayCho_MD]

@HKennecke @drcarl_vancouvr @CDNCancerTrials @NCICTEP_ClinRes @JoshSmithMDPhD @MarkWhitefordMD @GillSharlene @CathyEngMD @KarynAGoodman @jonathanloree @ColonCancerDoc @VanMorrisMD @OHSUKnight Congrats @HKennecke! Can’t wait to see the results!!!

[May Cho @MayCho_MD]

Congrats @Cecchini_OncMD! You have incubated this project since fellowship!

[Yale Cancer Center @YaleCancer]

A new study from @Cecchini_OncMD and colleagues at Yale Cancer Center found olaparib and ramucirumab is well-tolerated with efficacy for metastatic #gastriccancer and #GEJadenocarcinoma. @SmilowCancer @YaleMed @YNHH
https://t.co/8wldxulk6k

[Yale Cancer Center @YaleCancer]

A new study from @Cecchini_OncMD and colleagues at Yale Cancer Center found olaparib and ramucirumab is well-tolerated with efficacy for metastatic #gastriccancer and #GEJadenocarcinoma. @SmilowCancer @YaleMed @YNHH
https://t.co/8wldxulk6k

[May Cho @MayCho_MD]

@Aiims1742 @jgong15 @MDAndersonNews @DanZhaoMD @PanCAN @Nature_NPJ Congrats @DanZhaoMD!

[May Cho @MayCho_MD]

@JaniceM10 @kspencer725 @kspencer725 may see this tweet 10 months later! 🤣

[ILSON David @ILSONDavid]

In MSI high mCRC Ipi Nivo was dramatically superior to chemo first line with marked improved PFS. Results of Nivo alone awaited. Establishes a new first line option in MSI high mCRC.

[Arndt Vogel @ArndtVogel]

Liver Metastases & Immune Checkpoint Inhibitor Efficacy in Refractory mCRC
@JAMANetworkOpen
https://t.co/yrYOO2tBkP
🔎CCTG CO.26 trial
👉Pts without LM have significantly improved
DCR, PFS & OS with Durva/Treme vs BSC
🧐consistent finding, important for future trial design
@myESMO